Supporting the rapid development and approval of effective and safe treatments for and vaccines against COVID-19 is EMA’s top priority to help save lives during the pandemic. Over recent weeks and months, the Agency has engaged with many developers of therapeutic medicines and there are a number of developments underway. However, at this point, on the basis of the preliminary data presented to the Agency, no medicine has yet demonstrated efficacy in treating COVID-19.
To combat Covid-19 pandemic, the World Health Organisation (WHO) insists that widescale “testing, testing, and testing” is the key as early diagnosis may help save lives. Aligning with the call of WHO, the Centre for Cellular and Molecular Biology (CCMB) is working overtime on the development of cost-effective and accurate diagnostic kits for wide distribution.
EMA is aware of recent media reports and publications which question whether some medicines, for instance angiotensin converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs, or sartan medicines), could worsen coronavirus disease (COVID-19). ACE inhibitors and ARBs are most commonly used for treating patients with high blood pressure, heart failure or kidney disease.
Do Not Forget to Verify
(Click on Subscription link in your inbox)
--------
Also Join: 
.png)
